🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India flag India · Delayed Price · Currency is INR
1,871.50
+1.50 (0.08%)
Nov 18, 2026, 3:28 PM IST

NSE:SUNPHARMA Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
616,309584,620525,784484,969438,857386,545
Revenue Growth
12.13%11.19%8.42%10.51%13.53%15.39%
Cost of Revenue
127,410124,786115,585114,422113,187108,761
Gross Profit
488,899459,834410,200370,547325,670277,784
Selling, General & Admin
124,532115,183100,50995,02583,54973,544
Other Operating Expenses
190,953179,157157,883144,755123,779101,331
Operating Expenses
345,534323,718284,145265,345232,613196,223
Operating Income
143,365136,116126,055105,20293,05881,560
Interest Expense
-3,386-3,389-2,314-2,385-1,720-1,274
Interest & Investment Income
9,7449,74412,97011,2625,3107,687
Earnings From Equity Investments
-500.6-558.7-153.5-384.1-479-165.4
Currency Exchange Gain (Loss)
7,81112,4021,855361.3-1,2611,540
Other Non Operating Income (Expenses)
3,909843.7620.6546.7756.5735.9
EBT Excluding Unusual Items
160,943155,158139,034114,60395,66490,084
Merger & Restructuring Charges
-5,132--3,617-739.5-643.9-563.5
Gain (Loss) on Sale of Investments
8,6368,6365,117921.9-240.37.7
Gain (Loss) on Sale of Assets
-64.5-64.5-164-99.775.4347.5
Asset Writedown
-193.4-1,708-71.3-1,564-312.5-2,179
Legal Settlements
-693.8-693.8-58.2---1,563
Other Unusual Items
-13,799-10,866-3,104-2,712-1,071-41,657
Pretax Income
149,866150,630137,368110,49593,60544,648
Income Tax Expense
39,99535,54427,72014,3958,47610,755
Earnings From Continuing Operations
109,871115,087109,64896,10085,12933,893
Minority Interest in Earnings
-209.7-292.3-357.1-336.5-393.6-1,166
Net Income
109,662114,794109,29095,76484,73632,727
Net Income to Common
109,662114,794109,29095,76484,73632,727
Net Income Growth
4.94%5.04%14.12%13.01%158.92%12.70%
Shares Outstanding (Basic)
2,3972,3992,3992,3992,3992,399
Shares Outstanding (Diluted)
2,3972,3992,3992,3992,3992,399
Shares Change
-0.10%-----
EPS (Basic)
45.7547.8445.5539.9135.3213.64
EPS (Diluted)
45.7147.8045.5539.9035.3013.60
EPS Growth
4.95%4.94%14.16%13.03%159.56%12.40%

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
77,73588,098119,43599,33228,73874,895
Free Cash Flow Per Share
32.4336.7249.7841.4011.9831.21
Dividend Per Share
-16.00016.00013.50011.50010.000
Dividend Growth
-0%18.52%17.39%15.00%33.33%
Gross Margin
79.33%78.66%78.02%76.41%74.21%71.86%
Operating Margin
23.26%23.28%23.97%21.69%21.20%21.10%
Profit Margin
17.79%19.64%20.79%19.75%19.31%8.47%
Free Cash Flow Margin
12.61%15.07%22.72%20.48%6.55%19.38%
EBITDA
171,054163,135149,679128,760116,513101,536
EBITDA Margin
27.76%27.90%28.47%26.55%26.55%26.27%
D&A For EBITDA
27,68927,01923,62523,55923,45619,975
EBIT
143,365136,116126,055105,20293,05881,560
EBIT Margin
23.26%23.28%23.97%21.69%21.20%21.10%
Effective Tax Rate
26.69%23.60%20.18%13.03%9.05%24.09%
Revenue as Reported
639,092604,338545,435498,510445,202395,760